Pancreatic cancer is likely to become the second most frequent cause of cancer-associated
mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Background The technique of pancreatoduodenectomy (PD) has evolved. Previously, non-
resectability was determined by involvement of the portal vein–superior mesenteric vein …

Background: Pancreatic cancer has the highest mortality rate among all main cancer types
and is the fourth leading cause of cancer death in Australia. Objective: This review focuses …

Background Multimodal treatment concepts enhance options for surgery in locally advanced
pancreatic ductal adenocarcinoma (PDAC). This review provides an overview of technical …

Introduction: Vascular resection remains a subject of debate in the management of
Pancreatic Ductal Adenocarcinoma (PDAC). These French recommendations were drafted …

Background Pancreatic cancer is associated with high recurrence rates, and any surgery
should aim to prevent local recurrence. However, systematic resection of putatively tumor …

The distinct biology of pancreatic cancer with aggressive and early invasive tumor cells, a
tumor promoting microenvironment, late diagnosis, and high therapy resistance poses major …

Pancreatic cancer remains a therapeutic challenge. Surgical resection in combination with
systemic chemotherapy is the only option promising long‐term survival and potential cure …

Objective: To compare the rates of R0 resection in pancreatoduodenectomy (PD) for
pancreatic and periampullary malignant tumors by means of standard (ST-PD) versus artery …